Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 260,259 shares, an increase of 586.4% from the February 26th total of 37,915 shares. Approximately 7.3% of the shares of the company are short sold. Based on an average trading volume of 727,004 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 727,004 shares, the short-interest ratio is currently 0.4 days. Approximately 7.3% of the shares of the company are short sold.

Onconetix Stock Performance

Shares of NASDAQ ONCO opened at $0.57 on Wednesday. Onconetix has a fifty-two week low of $0.44 and a fifty-two week high of $14.86. The stock has a market cap of $2.05 million, a PE ratio of -0.01 and a beta of 3.51. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $2.09.

Onconetix (NASDAQ:ONCO) last issued its quarterly earnings data on Friday, March 13th. The company reported $12.58 earnings per share (EPS) for the quarter. The business had revenue of $0.30 million for the quarter. Onconetix had a positive return on equity of 8.24% and a negative net margin of 1,717.50%.

Hedge Funds Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix at the end of the most recent quarter. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.